AUA 2022
AUA 2022
AUA 2022: Surrogate Endpoints as Predictors of Survival in Metastatic Urothelial Cancer Trials
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Fady Ghali presented the results of his group’s systematic review evaluating the association between surrogate endpoints and overall survival in metastatic urothelial cancer trials.
AUA 2022: Frequency of Fibroblast Growth Factor Receptor Alterations and Association With Bacillus Calmette-Guerin Outcomes in a Real-World Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) Study
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Florus C. De Jong presented his own center’s real-world data evaluating the frequency of Fibroblast Growth Factor Receptor (FGFR) alterations in high-risk non-muscle-invasive bladder cancer (NMIBC) patients receiving BCG treatment and their associations with oncologic outcomes.
AUA 2022: Longitudinal Health-Related Quality of Life Outcomes in Adults with Non-Muscle-Invasive Bladder Cancer Receiving a Chemoablative Gel as a Primary Treatment (Optima II: Phase 2b, single arm, open-label trial)
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Smith presented the health-related quality of life outcomes results for low-grade non-muscle invasive bladder cancer (LG NMIBC) patients receiving UGN-102, a mitomycin containing reverse thermal gel.
AUA 2022: A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Recirculant Hyperthermic Intravesical Chemotherapy
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Andrew Stemberger presented the 2-year follow up results of BCG-unresponsive NMIBC patients treated with hyperthermic Mitomycin C.
AUA 2022: Neoadjuvant Pembrolizumab May Result in Long-Term Outcome Improvement in Biomarker-Unselected Patients With Muscle-Invasive Bladder Cancer: Updated results from PURE-01
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Luigi Nocera provided updated outcomes results of PURE-01, an open-label, single-arm, phase 2 study, where cT2-4aN0M0 MIBC patients received three courses of 200 mg pembrolizumab preceding radical cystectomy. Pathologic response rates have been reported previously in this study with pT0 and <=pT1 rates of 37% and 55%, respectively. The aim of this report is to present updated results on recurrence-free survival (RFS) and overall survival (OS) at longer follow-up.
AUA 2022: Prevalence and Predictors of Psychological Distress Among Patients Treated for Bladder Cancer
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Nihal Mohamed presented the results of her study evaluating the prevalence and predictors of psychological distress among patients treated for bladder cancer.
AUA 2022: Immediate Radical Cystectomy vs. BCG Immunotherapy for T1 High Grade Non-Muscle-Invasive Bladder Cancer: an International Multicentre Collaboration
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Chiara Lonati presented the results of a retrospective analysis comparing the cancer-specific mortality (CSM) and overall mortality (OM) between T1 squamous bladder cancer patients undergoing immediate radical cystectomy versus conservative treatment with BCG.
AUA 2022: CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to BCG
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Roger Li presented the interim analysis of the CORE1: Phase 2, single arm study evaluating the combination of CG0070 with IV pembrolizumab in BCG unresponsive CIS patients.
AUA 2022: A Phase II Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guerin Unresponsive Carcinoma in Situ of the Bladder
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Roger Li presented the results of a phase II trial evaluating Durvalumab in patients with BCG-unresponsive CIS of the bladder.
AUA 2022: Two-Year Efficacy Follow-Up of a Phase I Trial of Intravesical BCG Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade NMIBC after Previous BCG Treatment
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a moderated poster session for non-invasive bladder cancer. Dr. Jazzmyne Montgomery presented the results of a 2-year efficacy follow-up of a phase I dose-escalation trial of intravesical BCG in combination with systemic pembrolizumab in recurrent and persistent HG NMIBC after previous BCG treatment (NCT02324582). The objective of this study was to evaluate the safety profile and disease-free survival (DFS) and overall survival (OS) efficacy results after a 2-year follow up.
AUA 2022: Development of Patient-Derived Kidney Cancer Organoid; Application to Drug Screening Models and Its Challenges
- Details
(UroToday.com) The 2022 American Urological Association Annual Meeting included a kidney cancer session featuring work from Dr. Akira Kazama and colleagues presenting results of their study investigating the development of 3D tumor organoids from renal cell carcinoma (RCC) tumors. While surgical resection of localized RCC can be curative, up to one-third of patients eventually recur. This raises the question of how treatment for a particular patient can become personalized and improve over time. Thus, these tumor organoids are being developed with the hopes that they will behave similarly to the primary RCC tumors and serve as reliable models. This exciting work has the potential to serve many purposes as they tested tyrosine kinase inhibitors (TKIs), targeted therapeutics for metastatic RCC, and for drug testing. Attempting to improve the life prognosis of patients diagnosed with RCC, this study seeks to address the challenges in developing personalized therapy for these patients.
AUA 2022: The Patient Voice: Experiences with Ureteral Stent Removal – A Urinary Stone Disease Research Network (USDRN) Study
- Details
(UroToday.com) Sunday afternoon wrapped up with a podium session covering the epidemiology and evaluation of stone disease. Dr. Charles Scales of Duke presented research focused on more deeply understanding the patient experience regarding ureteral stent removal. The researchers in this investigation sought to qualitatively understand the patient experience to help spark and guide better patient care.
AUA 2022: Determining the Threshold of Safety for Intrarenal Pressure During Flexible Ureteroscopy Using an in Vivo Pig Model
- Details
(UroToday.com) Dr. Matthew Lee and team conducted a study concerning intrarenal pressure during kidney stone operations. Ureteroscopy (URS) is one of the most common surgical interventions for nephrolithiasis, where a ureteroscope enters the urethra and is used to find a path through the ureter and into the kidney. Irrigation is used during the procedure for visualization however, this creates intrarenal pressure (IRP). Excess IRP can lead to serious complications such as pyelovenous backflow, which is hypothesized to occur around 40 mmHg. A study by Jung et Al. demonstrated instances where the IRP went up over 300 mmHg, as seen in the table below.
AUA 2022: Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell Carcinoma
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a podium session for advanced kidney cancer. Dr. Sari Khaleel presented his team’s work evaluating outcomes of cytoreductive nephrectomy (CN) followed by active surveillance (AS) in metastatic renal cell carcinoma (RCC).
AUA 2022: 68 Ga-PSMA PET/CT for Preoperative Lymph Node Staging of High Risk Prostate Cancer
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a podium session on surgical therapies in localized prostate cancer. Dr. Maximilian Schmautz presented the results of his group’s study evaluating the role of 68Ga-PSMA PET/CT for the preoperative lymph node (LN) staging of high risk prostate cancer.
AUA 2022: Can Pelvic Lymph Node Dissection Be Omitted at the Time of Radical Prostatectomy in Patients With a Negative Preoperative 68Ga-PSMA PET/CT? The Importance of Patient Risk Stratification According to Individual Risk of Lymph Node Metastases
- Details
Dr. Gandaglia began his presentation by noting that the role of PSMA PET/CT in the primary staging for patients with prostate cancer is still debatable. Metaanalyses have demonstrated that in studies where LN involvement prevalence ranged between 5 and 20%, the negative predictive value of PSMA PET/CT remained steadily above 90%. Although previous studies suggested a high NPV in intermediate risk patients, the variation of FN rate according to the prevalence of LN invasion based on pre-operative risk assessment has never been tested.
AUA 2022: Final Results of a Phase I Trial of WST11 (TOOKAD Soluble) Vascular-Targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a podium session about upper tract transitional cell carcinoma. Dr. Wesley Yip presented the final results of a Phase 1 trial of WST11 (TOOKAD Soluble) vascular-targeted photodynamic therapy for the treatment of upper tract urothelial carcinoma.
AUA 2022: Impact of Node Count on Survival Outcomes of Lymph Node Dissection in non-Metastatic Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a podium session about upper tract transitional cell carcinoma. Kevin Hakimi presented results from the ROBUUST Registry evaluating the impact of node count on survival outcomes of lymph node (LN) dissection in non-metastatic upper tract urothelial carcinoma (UTUC).
AUA 2022: The Impact Of Histological Variants On The Performance Characteristics Of 68Ga-PSMA PET/CT In The Primary And Recurrent Setting
- Details
(UroToday.com) The 2022 Annual Meeting of the American Urological Association was host to a podium session of surgical therapies in localized prostate cancer. Dr. Simone Scuderi presented results of his group’s work evaluating the impact of histological variants on the performance of 68Ga-PSMA PET/CT in both the primary and recurrent settings.
AUA 2022: RARP Modifications That Enhance Continence Return
- Details
(UroToday.com) The 2022 American Urological Association (AUA) Annual Meeting included the International Prostate Forum session and a presentation by Dr. Kirsten Greene discussing robotic-assisted radical prostatectomy (RARP) modifications that enhance continence return.